Evidence map›Paper›PMID 28665419›Full record

ReviewBlood cancer journal2017

Acute lymphoblastic leukemia: a comprehensive review and 2017 update.

T Terwilliger, M Abdul-Hay

4 registry-linked trialsOpen access · goldAbstract readHistorical ArticleReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 648 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
648citing papers in PubMed, 7 pooled it
83.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04554381 phase1unknown statusnot on this mapstarted 2020, after this paper: background citation

Assesment of JL1 Expression in B-cell Acute Lymphoblastic Leukemia

TypeinterventionalSponsorAssiut UniversityRan2020 to 2023Enrolled50ConditionsAcute Lymphoblastic LeukemiaArmsJL1 antigen
NCT04764695 nacompletednot on this mapstarted 2023, after this paper: background citation

Evaluation of Body Composition and Nutritional Status in Pediatric Patients With Hematological Malignancies

TypeinterventionalSponsorUniversidad de SonoraRan2023 to 2024Enrolled38ConditionsChildhood Cancer, Child Malnutrition, Childhood ObesityArmsD2O dilution technique
NCT06387121 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Efficacy and Safety of Low-dose Chemotherapy Combined With Immuno-targeted Drugs in Newly Diagnosed Adult Patients With Ph-negative B-cell Acute Lymphocytic Leukemia: A Prospective, Single-arm Clinical Study

TypeinterventionalSponsorInstitute of Hematology & Blood Diseases Hospital, ChinaRan2024 to 2028Enrolled53ConditionsPrecursor Cell Lymphoblastic Leukemia-LymphomaArmsVincristine, Cyclophosphamide, Dexamethasone, Venetoclax, Inotuzumab ozogamicin
NCT07588360 narecruitingnot on this mapstarted 2025, after this paper: background citation

Haploidentical Combined With Cord Blood Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Prospective, Multicenter Clinical Study

TypeinterventionalSponsorFujian Medical University Union HospitalRan2025 to 2029Enrolled82ConditionsMDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)Armshaplo-cord HSCT, Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)
3 · Its place in the literature

Who cites it

648 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,255 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

588 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

T TerwilligerNew York University School of Medicine, New York, USA.
M Abdul-HayNew York University School of Medicine, New York, USA.
New York University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence of over 6500 cases per year in the United States alone. The hallmark of ALL is chromosomal abnormalities and genetic alterations involved in differentiation and proliferation of lymphoid precursor cells. In adults, 75% of cases develop from precursors of the B-cell lineage, with the remainder of cases consisting of malignant T-cell precursors. Traditionally, risk stratification has been based on clinical factors such age, white blood cell count and response to chemotherapy; however, the identification of recurrent genetic alterations has helped refine individual prognosis and guide management. Despite advances in management, the backbone of therapy remains multi-agent chemotherapy with vincristine, corticosteroids and an anthracycline with allogeneic stem cell transplantation for eligible candidates. Elderly patients are often unable to tolerate such regimens and carry a particularly poor prognosis. Here, we review the major recent advances in the treatment of ALL.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaFemaleHistory, 21st CenturyHumansMale

Identifiers

PMID28665419
PMCPMC5520400
OpenAlexW2725970815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.